E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction A TIMI 14 Substudy
C. Michael Gibson,James A. de Lemos,Sabina A. Murphy,Susan J. Marble,Carolyn H. McCabe,Christopher P. Cannon,Elliott M. Antman,Eugene Braunwald +7 more
TL;DR: Compared with thrombolytic monotherapy, combination therapy with abciximab reduces AET, which in turn is associated with reduced residual stenosis and improved ST-segment resolution in AMI, providing a pathophysiological link between platelet inhibition, reduced thrombus, and improvements in both epicardial and microvascular perfusion in AMi.
Journal ArticleDOI
The Effects of Nitroglycerin and Amyl Nitrite on Arteriolar and Venous Tone in the Human Forearm
TL;DR: The effects of sublingual nitroglycerin and inhaled amyl nitrite on the arteriolar and venous beds of the forearm were studied and venoconstriction was abolished or diminished when adrenergic activity was impeded by administration of either guanethidine or reserpine.
Journal ArticleDOI
Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation Acute Coronary Syndromes: The MERLIN-TIMI 36 Randomized Trial
David A. Morrow,Benjamin M. Scirica,Ewa Karwatowska-Prokopczuk,Sabina A. Murphy,Andrzej Budaj,Sergei Varshavsky,Andrew A. Wolff,Allan M. Skene,Carolyn H. McCabe,Eugene Braunwald +9 more
TL;DR: A randomized, double-blind, placebo-controlled, multinational clinical trial of 6560 patients within 48 hours of ischemic symptoms who were treated with ranolazine (initiated intravenously and followed by runningolazine extended-release 1000 mg twice daily, n = 3279) or matching placebo (n = 3281) was conducted in this paper.
Journal ArticleDOI
Medical and cellular implications of stunning, hibernation, and preconditioning - An NHLBI Workshop
TL;DR: The purpose of this article is to review some of the points made at the workshop in regard to areas of general agreement and controversy and, most importantly, to summarize the areas that need further research.
Journal ArticleDOI
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
Stephen D. Wiviott,Eugene Braunwald,Carolyn H. McCabe,Iván Horváth,Matyas Keltai,Jean Paul R. Herrman,Frans Van de Werf,William E. Downey,Benjamin M. Scirica,Sabina A. Murphy,Elliott M. Antman +10 more
TL;DR: Intensive antiplatelet therapy with prasugrel resulted in fewer ischaemic outcomes including stent thrombosis than with standard clopidogrel, and the data affirm the importance of intensive platelet inhibition in patients with intracoronary stents.